Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frovatriptan Vernalis.

Hermann A M Mucke1

  • 1HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria. h.mucke@hmpharmacon.com

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed
Summary

Frovatriptan, a selective serotonin 5-HT1B/1D receptor partial agonist, is being developed as a novel migraine treatment. This drug offers a potential new therapeutic option for individuals suffering from migraine headaches.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patent highlights June - July 2024.

Pharmaceutical patent analyst·2025
Same author

Patent highlights April-May 2024.

Pharmaceutical patent analyst·2025
Same author

Drug Repurposing Patent Applications January-March 2025.

Assay and drug development technologies·2025
Same author

Drug Repurposing Patent Applications October-December 2024.

Assay and drug development technologies·2025
Same author

Patent highlights June - July 2024.

Pharmaceutical patent analyst·2025
Same author

Drug Repurposing Patent Applications July-September 2024.

Assay and drug development technologies·2024

Area of Science:

  • Pharmacology
  • Neurology
  • Drug Development

Background:

  • Migraine is a common neurological disorder characterized by severe headaches.
  • Existing treatments for migraine have limitations, necessitating the development of new therapeutic agents.
  • Selective serotonin receptor agonists are a key class of drugs used in migraine management.

Purpose of the Study:

  • To introduce frovatriptan, a novel selective 5-HT1B/1D partial agonist.
  • To highlight its development status as a potential migraine therapeutic.

Main Methods:

  • Drug development and characterization of frovatriptan.
  • Evaluation of its pharmacological profile as a selective 5-HT1B/1D partial agonist.

Main Results:

  • Frovatriptan exhibits selective binding and partial agonism at 5-HT1B and 5-HT1D receptors.
  • The drug has been developed by Vanguard (now Vernalis) and licensed from GlaxoSmithKline.

Conclusions:

  • Frovatriptan represents a promising new pharmacological agent for migraine treatment.
  • Its selective action on 5-HT1B/1D receptors suggests a targeted approach to migraine therapy.

Related Experiment Videos